Skip to content
Evigrade
MajorCentrally acting sympathomimetics×Selective serotonin reuptake inhibitors

Updated · Methodology

Mechanism

The liver breaks down atomoxetine mainly through the enzyme CYP2D6, and fluoxetine is a strong inhibitor of this enzyme (atomoxetine and fluoxetine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). With fluoxetine, atomoxetine exposure rose 6- to 8-fold and its peak concentration 3- to 4-fold, close to the levels seen in people whose CYP2D6 does not work (atomoxetine SmPC, AEMPS, and atomoxetine label, US Food and Drug Administration, FDA). Fluoxetine and its active metabolite norfluoxetine leave the body slowly, with half-lives of 4–6 and 4–16 days, so they stay in the body for weeks after the last dose (fluoxetine SmPC, AEMPS, and fluoxetine FDA label). Both drugs can prolong the QT interval. With fluoxetine, QT prolongation and ventricular arrhythmias, including torsade de pointes, have been reported (fluoxetine SmPC, AEMPS). QT prolongation is among the adverse reactions of atomoxetine. In a dedicated study, the corrected QT interval (QTc) rose slightly as atomoxetine concentration increased (atomoxetine SmPC, AEMPS). Serotonin syndrome has been reported in people who took atomoxetine with selective serotonin reuptake inhibitors (SSRIs), the group fluoxetine belongs to (atomoxetine SmPC, AEMPS).

Symptoms

People whose CYP2D6 does not work (poor metabolizers) reach atomoxetine exposures similar to those seen with a strong inhibitor of this enzyme (atomoxetine label, US Food and Drug Administration, FDA). Compared with adult extensive metabolizers, whose CYP2D6 works normally, adult poor metabolizers had dry mouth in 34.5% versus 17.4%, insomnia in 19.2% versus 11.3%, erectile dysfunction in 20.9% versus 8.9% and urinary retention in 5.9% versus 1.2%. In children, decreased appetite, insomnia, tremor and fainting were also more common in poor metabolizers (atomoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Heart rate rose more in adult poor metabolizers than in other metabolizer types, on average by 11 versus 7.5 beats per minute (atomoxetine FDA label). QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting. Serotonin syndrome causes fever, muscle rigidity, muscle jerks, swings in pulse and blood pressure, confusion and severe agitation (fluoxetine SmPC, AEMPS).

Management

The fluoxetine summary of product characteristics (SmPC) names atomoxetine: with fluoxetine, start or adjust atomoxetine at the lowest therapeutic dose. This also applies if the patient took fluoxetine in the previous 5 weeks (fluoxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With a strong inhibitor of the enzyme CYP2D6, the US Food and Drug Administration (FDA) atomoxetine label keeps the usual starting, target and maximum doses but extends the titration interval to 4 weeks. Increase the dose only if symptoms of attention deficit hyperactivity disorder (ADHD) have not improved and the starting dose is well tolerated (atomoxetine FDA label). If fluoxetine is started or stopped after the atomoxetine dose has been set, reassess response and tolerability and decide whether the dose needs adjusting (atomoxetine SmPC, AEMPS). The fluoxetine FDA label says to avoid combining it with drugs that prolong the QT interval. The SmPCs of both drugs ask for caution with such combinations (fluoxetine and atomoxetine SmPCs, AEMPS). If both drugs are still needed, consider an electrocardiogram (ECG) before starting fluoxetine and periodically during treatment (fluoxetine FDA label). If signs of arrhythmia appear, stop fluoxetine and record an ECG (fluoxetine SmPC, AEMPS). Measure pulse and blood pressure before starting atomoxetine, after each dose change and at least every 6 months (atomoxetine SmPC, AEMPS). If serotonin syndrome appears, stop fluoxetine and start symptomatic treatment (fluoxetine SmPC, AEMPS). For atomoxetine, consider a lower dose or stopping it, depending on severity (atomoxetine SmPC, AEMPS). Use atomoxetine with caution together with selective serotonin reuptake inhibitors (SSRIs), which lower the seizure threshold (atomoxetine SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atomoxetine

Other interactions with Fluoxetine